RU99113343A - MEDICINAL FORMS OF CYCLOSPORIN FOR ORAL ADMINISTRATION - Google Patents

MEDICINAL FORMS OF CYCLOSPORIN FOR ORAL ADMINISTRATION

Info

Publication number
RU99113343A
RU99113343A RU99113343/14A RU99113343A RU99113343A RU 99113343 A RU99113343 A RU 99113343A RU 99113343/14 A RU99113343/14 A RU 99113343/14A RU 99113343 A RU99113343 A RU 99113343A RU 99113343 A RU99113343 A RU 99113343A
Authority
RU
Russia
Prior art keywords
dosage form
form according
specified
polyethylene glycol
oral administration
Prior art date
Application number
RU99113343/14A
Other languages
Russian (ru)
Other versions
RU2174405C2 (en
Inventor
Моо Дж. ЧУ
Ральф Э. ЛИВИ
Филипп Дж. ПУЛЕТТИ
Original Assignee
Сэнгстат Медикал Корпорейшн
Те Юниверсити Оф Норт Каролина Эт Чепел Хилл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/956,841 external-priority patent/US5962019A/en
Application filed by Сэнгстат Медикал Корпорейшн, Те Юниверсити Оф Норт Каролина Эт Чепел Хилл filed Critical Сэнгстат Медикал Корпорейшн
Publication of RU99113343A publication Critical patent/RU99113343A/en
Application granted granted Critical
Publication of RU2174405C2 publication Critical patent/RU2174405C2/en

Links

Claims (16)

1. Лекарственная форма циклоспорина для перорального введения, состоящая в основном из циклоспорина; по крайней мере одного спиртового растворителя, имеющего 2 - 3 атома углерода; по крайней мере одного неионного полиоксиалкиленового поверхностно-активного вещества, в котором указанное поверхностно-активное вещество выбирают из группы, состоящей из полиоксиэтиленовых спиртов и моноэфиров жирных кислот и этоксилированных полиолов, имеющих 4 - 6 атомов углерода; и по крайней мере одного полигликоля, причем по крайней мере один из указанных по крайней мере одного полигликоля имеет молекулярную массу в интервале 800 - 10000 Дальтон.1. Dosage form of cyclosporine for oral administration, consisting mainly of cyclosporine; at least one alcohol solvent having 2 to 3 carbon atoms; at least one non-ionic polyoxyalkylene surfactant in which said surfactant is selected from the group consisting of polyoxyethylene alcohols and monoesters of fatty acids and ethoxylated polyols having 4 to 6 carbon atoms; and at least one polyglycol, with at least one of the at least one polyglycol having a molecular weight in the range of 800 to 10,000 Daltons. 2. Лекарственная форма по п.1, в которой указанный полигликоль включает в себя полиэтиленгликоль. 2. The dosage form according to claim 1, wherein said polyglycol includes polyethylene glycol. 3. Лекарственная форма по п.2, в которой указанный спиртовой растворитель составляет от около 5 до 75 об.% указанной лекарственной формы. 3. The dosage form according to claim 2, in which the specified alcohol solvent is from about 5 to 75 vol.% The specified dosage form. 4. Лекарственная форма по п.2, в которой указанный спиртовой растворитель составляет от около 10 до 25 об.% указанной лекарственной формы. 4. The dosage form according to claim 2, in which the specified alcohol solvent is from about 10 to 25 vol.% The specified dosage form. 5. Лекарственная форма по п.4, в которой указанный спиртовой растворитель представляет собой абсолютный этанол. 5. The dosage form according to claim 4, in which the indicated alcohol solvent is absolute ethanol. 6. Лекарственная форма по п.2, в которой указанное по крайней мере одно неионное полиоксиалкиленовое поверхностно-активное вещество составляет от около 5 до 80 вес.% указанной лекарственной формы. 6. The dosage form according to claim 2, wherein said at least one non-ionic polyoxyalkylene surfactant comprises from about 5 to 80% by weight of said dosage form. 7. Лекарственная форма по п.2, в которой указанное по крайней мере одно неионное полиоксиалкиленовое поверхностно-активное вещество составляет от около 10 до 50 вес.% указанной лекарственной формы. 7. The dosage form according to claim 2, wherein said at least one non-ionic polyoxyalkylene surfactant comprises from about 10 to 50% by weight of said dosage form. 8. Лекарственная форма по п.2, в которой указанное по крайней мере одно неионное полиоксиалкиленовое поверхностно-активное вещество составляет от около 20 до 75 об.% указанной лекарственной формы. 8. The dosage form according to claim 2, in which said at least one non-ionic polyoxyalkylene surfactant comprises from about 20 to 75 vol.% Of the specified dosage form. 9. Лекарственная форма по п.2, в которой указанное по крайней мере одно неионное полиоксиалкиленовое поверхностно-активное вещество выбирают из группы, состоящей из полиоксиэтилен (20) моносорбитан моно-олеата и эфира лауриловой кислоты и полиоксиэтилена (4). 9. The dosage form according to claim 2, wherein said at least one non-ionic polyoxyalkylene surfactant is selected from the group consisting of polyoxyethylene (20) monosorbitan mono-oleate and lauryl acid ester and polyoxyethylene (4). 10. Лекарственная форма по п.2, в которой указанный по крайней мере один полиэтиленгликоль включает в себя полиэтиленгликоль, имеющий молекулярную массу в интервале 1000 - 8000 Дальтон. 10. The dosage form according to claim 2, in which said at least one polyethylene glycol includes polyethylene glycol having a molecular weight in the range of 1000-8000 Daltons. 11. Лекарственная форма по п.2, в которой указанный по крайней мере один полиэтиленгликоль представляет собой смесь двух различных полиэтиленгликолей, имеющих разные молекулярные массы. 11. The dosage form according to claim 2, wherein said at least one polyethylene glycol is a mixture of two different polyethylene glycols having different molecular weights. 12. Лекарственная форма по п.2, в которой указанный по крайней мере один полиэтиленгликоль составляет 20 - 80 вес.% указанной лекарственной формы. 12. The dosage form according to claim 2, in which the specified at least one polyethylene glycol is 20 to 80 wt.% The specified dosage form. 13. Лекарственная форма по п.1, в которой циклоспорин присутствует в концентрации 100 мг/мл, абсолютный спирт присутствует в концентрации 12,5%, а полиоксиэтилен (20) моносорбитан моно-олеат присутствует в концентрации 400 мг/мл. 13. The dosage form according to claim 1, in which cyclosporine is present at a concentration of 100 mg / ml, absolute alcohol is present at a concentration of 12.5%, and polyoxyethylene (20) monosorbitan mono-oleate is present at a concentration of 400 mg / ml. 14. Лекарственная форма по п.1, которая находится в твердой капсуле. 14. The dosage form according to claim 1, which is in a hard capsule. 15. Лекарственная форма циклоспорина для перорального введения, включающая в себя циклоспорин и физиологически пригодный носитель, причем указанная лекарственная форма является существенно безводной. 15. A dosage form of cyclosporin for oral administration comprising cyclosporin and a physiologically acceptable carrier, said dosage form being substantially anhydrous. 16. Использование лекарственной формы циклоспорина для перорального введения, согласно любого из пп.1 - 15. 16. The use of the dosage form of cyclosporine for oral administration, according to any one of claims 1 to 15.
RU99113343/14A 1997-10-23 1998-10-21 Cyclosporin composition for oral administration (versions) and method of attainment of immunosuppression in recipient body RU2174405C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/956,841 US5962019A (en) 1995-08-25 1997-10-23 Oral cyclosporin formulations
US08/956,841 1997-10-23

Publications (2)

Publication Number Publication Date
RU99113343A true RU99113343A (en) 2001-04-20
RU2174405C2 RU2174405C2 (en) 2001-10-10

Family

ID=25498759

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99113343/14A RU2174405C2 (en) 1997-10-23 1998-10-21 Cyclosporin composition for oral administration (versions) and method of attainment of immunosuppression in recipient body

Country Status (20)

Country Link
US (1) US5962019A (en)
EP (1) EP0956035A1 (en)
JP (1) JP2000516267A (en)
KR (1) KR20000069688A (en)
CN (1) CN1246057A (en)
AR (1) AR013710A1 (en)
AU (1) AU9810698A (en)
BR (1) BR9806271A (en)
CA (1) CA2275773A1 (en)
HU (1) HUP0004733A3 (en)
IL (1) IL130631A0 (en)
NO (1) NO993096L (en)
NZ (1) NZ336253A (en)
PL (1) PL334100A1 (en)
RU (1) RU2174405C2 (en)
SK (1) SK97199A3 (en)
TR (1) TR199901448T1 (en)
TW (1) TW592707B (en)
WO (1) WO1999020296A1 (en)
ZA (1) ZA989684B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
SK285019B6 (en) 1997-01-30 2006-04-06 Novartis Ag Hard gelatine capsule
IL143604A0 (en) 1998-12-30 2002-04-21 Dexcel Ltd Dispersable concentrate for the delivery of cyclosporin
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
IL148685A0 (en) * 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
PT1438966E (en) 1999-12-08 2007-05-31 Cyclacel Pharmaceuticals Inc Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease.
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6960563B2 (en) * 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
MY145753A (en) * 2001-10-19 2012-03-30 Isotechnika Inc Novel cyclosporin analog formulations
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006110802A1 (en) 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
MX2008011054A (en) * 2006-03-02 2009-03-03 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity.
CN101032620B (en) * 2007-03-08 2010-05-19 上海凯昭医药科技有限公司 Cyclosporine emulsion and the preparing method
CA2681361A1 (en) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Methods for treating neovascular ocular diseases
AU2008309923B2 (en) * 2007-10-08 2014-04-03 Fovea Pharmaceuticals Aqueous ophthalmic formulations
EP3305312A4 (en) * 2015-06-05 2019-02-27 Maruho Co., Ltd. External preparation for transdermal administration

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US506219A (en) * 1893-10-10 Steam-cooker
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (en) * 1977-05-10 1978-11-23 Sandoz Ag CYCLOSPORIN DERIVATIVES, THEIR USE AND MANUFACTURING
FI65914C (en) * 1978-03-07 1984-08-10 Sandoz Ag FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5118493A (en) * 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
HU205861B (en) * 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
US4792449A (en) * 1987-01-28 1988-12-20 Baxter Travenol Laboratories, Inc. Method for drug administration
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
KR880012221A (en) * 1987-04-13 1988-11-26 사노 가즈오 Pharmaceutical compositions containing esters or amides as active ingredients
JP2577049B2 (en) * 1987-06-04 1997-01-29 三共株式会社 Cyclosporine preparation
HU205010B (en) * 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
GB8729153D0 (en) * 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
ES2033086T3 (en) * 1988-01-29 1993-03-01 Sankyo Company Limited A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION.
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
BE1003578A4 (en) * 1988-10-26 1992-04-28 Sandoz Sa New ophthalmic compositions of cyclosporine.
BE1003009A5 (en) * 1989-02-09 1991-10-22 Sandoz Sa NOVEL PHARMACEUTICAL COMPOSITIONS BASED ON CYCLOSPORINS.
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
EP0544671A4 (en) * 1990-04-18 1993-09-15 The University Of Utah Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling
JPH04253907A (en) * 1990-05-23 1992-09-09 Green Cross Corp:The Immunosuppressive agent for intravenous injection
US5393791A (en) * 1990-07-19 1995-02-28 Helena Chemical Company Homogeneous, essentially nonaqueous adjuvant compositions with buffering capability
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
MX9201782A (en) * 1991-04-19 1992-10-01 Sandoz Ag PARTICLES OF BIOLOGICALLY ACTIVE SUBSTANCES, SUBSTANTIALLY INSOLUBLE IN WATER, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
JPH0558906A (en) * 1991-09-06 1993-03-09 Sankyo Co Ltd Cyclosporin eye-lotion
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
EP0642332B1 (en) * 1992-05-13 1997-01-15 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
IT1260505B (en) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa ORAL PHARMACEUTICAL SYSTEMS WITH DELAYED DELIVERY FOR THE SPECIFIC RELEASE IN THE COLON
EP1142568A1 (en) * 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
SK283442B6 (en) * 1993-04-20 2003-07-01 Novartis Ag Pharmaceutical composition for oral administration
CN1077800C (en) * 1993-07-01 2002-01-16 韩美药品工业株式会社 Cyclosporin soft capsule composition
DE4329503A1 (en) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmaceutical preparations for the targeted treatment of Crohn's disease and ulcerative colitis
DE4340781C3 (en) * 1993-11-30 2000-01-27 Novartis Ag Liquid preparations containing cyclosporin and process for their preparation
KR0146671B1 (en) * 1994-02-25 1998-08-17 김충환 Cyclosporin-containing powder composition
RU2158601C2 (en) * 1994-11-03 2000-11-10 Новартис Аг Novel medicinal forms of cyclosporine for oral administration having simple formulation and bioavailability, and method of preparation thereof
HU215966B (en) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Oral multiple emulsion-preconcentrate containing cyclosporin
KR0167613B1 (en) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
MX9702809A (en) * 1995-08-25 1998-02-28 Sangstat Medical Corp Oral cyclosporin formulations.
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
IL131609A0 (en) * 1997-03-12 2001-01-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine

Similar Documents

Publication Publication Date Title
RU99113343A (en) MEDICINAL FORMS OF CYCLOSPORIN FOR ORAL ADMINISTRATION
RU2211047C2 (en) Gelatin capsule with solid film including oil-free pharmaceutically compositions
FI97524B (en) A process for preparing a cyclosporin-containing pharmaceutical composition
CN1113650C (en) Self-emulsifying formulation forlipophilic compounds
KR100602725B1 (en) Self-emulsifying compositions for drugs poorly soluble in water
CA2284000A1 (en) Hydrophilic binary systems for the administration of cyclosporine
HUP0004733A2 (en) Oral cyclosporin formulations
KR0150830B1 (en) Cyclosporin soft capsule composition
US20010005726A1 (en) Oral micro-emulsion composition of silybin
US20150165050A1 (en) Cyclosporin compositions
JP2006206615A (en) Pharmaceutical preparation comprising cyclosporin for oral administration
RU2001124597A (en) Spontaneously dispersible compositions containing N-benzoylstaurosporin
JP2002537242A5 (en)
KR100847679B1 (en) Oral dosage self-emulsifying formulations of pyranone protease inhibitors
KR970706803A (en) Oral Cyclosporin Formulations (Oral Cyclosporin Formulations)
KR100495417B1 (en) Cyclosporin formulation
RU99114019A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES N-SULFONILINDOLINE
EA200200415A1 (en) COMPOSITION OF PHARMACEUTICAL MEDIA
RU2216342C2 (en) Cyclosporin solution
US6979672B2 (en) Cyclosporin-based pharmaceutical compositions
FR2726470A1 (en) COMPOSITION BASED ON INTERFERON
KR0163210B1 (en) Liquid composition comprising cyclosporin
JPH0510329B2 (en)
RU97107086A (en) ORAL CYCLOSPORIN COMPOSITIONS
MXPA99006916A (en) Oil-free pharmaceutical compositions containing cyclosporin a